1187829-40-8

Basic information

• Product Name: (3,4‐dimethoxyphenyl)[4‐(3,4‐dimethoxyphenyl)‐1H‐imidazol‐2‐yl]methanone
• Synonyms: (3,4‐dimethoxyphenyl)[4‐(3,4‐dimethoxyphenyl)‐1H‐imidazol‐2‐yl]methanone
• CAS NO: 1187829-40-8
• Molecular Weight: 368.389
• Mol File: 1187829-40-8.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: (3,4‐dimethoxyphenyl)[4‐(3,4‐dimethoxyphenyl)‐1H‐imidazol‐2‐yl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (3,4‐dimethoxyphenyl)[4‐(3,4‐dimethoxyphenyl)‐1H‐imidazol‐2‐yl]methanone(1187829-40-8)
• EPA Substance Registry System: (3,4‐dimethoxyphenyl)[4‐(3,4‐dimethoxyphenyl)‐1H‐imidazol‐2‐yl]methanone(1187829-40-8)

Safety Data

• Hazardous Substances Data: 1187829-40-8(Hazardous Substances Data)

Upstream product

• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 163428-90-8 2,2-dihydroxy-1-(3,4-dimethoxyphenyl)ethan-1-one 
• 187101-52-6 2-azido-1-(3,4-dimethoxyphenyl)ethanone 
• 15462-03-0 3',4'-dimethoxyphenylglyoxal 

Relevant articles and documents

A novel class for carbonic anhydrases inhibitors and evaluation of their non-zinc binding

In this study, 23 different imidazole derivatives were synthesized, and the inhibitory properties of these derivatives against carbonic anhydrase I and II isoenzymes were investigated for the first time. The inhibition concentrations of the imidazole derivatives were found to be in the range of 2.89–115.5 nM. Docking studies examined the binding properties of the imidazole derivatives, and the structure–activity relationship is discussed. Theoretical calculations showed that the binding mode of the imidazole ring was non-zinc binding.

Mono- or di-substituted imidazole derivatives for inhibition of acetylcholine and butyrylcholine esterases

Mono- or di-substituted imidazole derivatives were synthesized using a one-pot, two-step strategy. All imidazole derivatives were tested for AChE and BChE inhibition and showed nanomolar activity similar to that of the test compound donepezil and higher than that of tacrine. Structure activity relationship studies, docking studies to on X-ray crystal structure of AChE with PDB code 1B41, and adsorption, distribution, metabolism, and excretion (ADME) predictions were performed. The synthesized core skeleton was bound to important regions of the active site of AChE such as the peripheral anionic site (PAS), oxyanion hole (OH), and anionic subsite (AS). Selectivity of the reported test compounds was calculated and enzyme kinetic studies revealed that they behave as competitive inhibitors, while two of the test compounds showed noncompetitive inhibitory behavior. ADME predictions revealed that the synthesized molecules might pass through the blood brain barrier and intestinal epithelial barrier and circulate freely in the blood stream without binding to human serum albumin. While the toxicity of one compound on the WS1 (skin fibroblast) cell line was 1790 μM, its toxicity on the SH-SY5Y (neuroblastoma) cell line was 950 μM.

An easy synthetic protocol for imidazo-1,4-oxazines and evaluation of their toxicities

Imidazo-1,5-alkynyl alcohol derivatives were synthesized, and they were cyclized to imidazo-1,4-oxazines by means of cesium carbonate. Propargyl-allene isomerization was examined, and the reaction mechanism was proposed. Moreover, cytotoxicity of synthesized molecules against LN405 cell lines was investigated by means of structure-activity relationship (SAR). With SAR study, toxicities of some functional groups have been shown. In addition, two lead compounds were tested against DNA damaging.